Tectonic Therapeutic, Inc. (TECX) Stock Price & Analysis
Tectonic Therapeutic, Inc. (TECX) closed at USD 21.3 on Thursday, October 15, 2026, up 1.62% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 20.96; the Oct 15, 2026 session ranged USD 21.06–21.51 on volume of 187,390 shares. Market capitalization is $416.40M, with a 52-week range of USD 15.52–39.53 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TECX.md
Key facts (TECX)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 71 (range 26–93).
- Total return with dividends: 1Y +20.7% vs S&P 500 +18.1%; 5Y -69.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.21, revenue estimate $0K.
Analysts (TECX)
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 71 (low 26, high 93).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiated | Neutral | $26 |
| 2026-08-07 | Wells Fargo | Target lowered | Overweight | $101 → $93 |
Total return (dividends reinvested) (TECX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +20.7% | -69.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +20.8% | -21.0% |
| Volatility (annualized) | 72.9% | 178.1% |
| Max drawdown | -44.7% (Jul 2026→Oct 2026) | -98.0% (Nov 2021→Jun 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 21.3 |
|---|---|
| Change | ▲ 1.62% (up) |
| Previous Close | USD 20.96 |
| Open | USD 21.08 |
| Day Range | USD 21.06 – 21.51 |
| 52-Week Range | USD 15.52 – 39.53 |
| Volume | 187,390 shares |
| Market Cap | $416.40M |
| Exchange | NGM |
Technical Analysis (TECX)
Nexqual's technical model rates TECX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.45 (oversold) |
| vs SMA50 | Below (USD 28.95) |
| MACD | -2.04 (negative) |
Analyst Ratings (TECX)
Wall Street analysts rate TECX "Buy" based on 10 analysts, with a mean price target of USD 71 (range USD 26–93), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 71 |
| High Target | USD 93 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (TECX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -1.21 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.18 vs est -1.36 ▲ beat |
| 2026-03-31 | USD -1.34 vs est -1.17 ▼ miss |
| 2025-12-31 | USD -1.03 vs est -1.11 ▲ beat |
| 2025-09-30 | USD -1.02 vs est -1.05 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (TECX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -33.80% |
| Debt / Equity | 0.02 |
| Current Ratio | 22.29 |
| Total Cash | $227.07M |
| Total Debt | $4.40M |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (TECX)
Nexqual rates Tectonic Therapeutic, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $227M cash vs $4M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$72M (TTM) |
| Efficiency | Critical — ROE -34%, ROA -22.3% |
Ownership (TECX)
| Insider Ownership | +37.60% |
|---|---|
| Institutional Ownership | +71.77% |
| Shares Outstanding | 19.55M |
| Float | 11.90M |
| Short % of Float | +22.99% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (TECX)
Tectonic Therapeutic, Inc. is led by Alise S. Reicin (age 64), President, CEO, Secretary & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO, Secretary & Director | Alise S. Reicin (age 64) |
|---|---|
| Chief Financial Officer | Daniel Lochner (age 43) |
| Senior Vice President of Technical Operations | Washington Alves M.S. |
| Chief Scientific Officer | Peter McNamara (age 53) |
| Senior Vice President of Human Resources | Geraldine Peters-Wiles |
Major Backers & Investors (TECX)
Notable institutional backers of Tectonic Therapeutic, Inc. include FMR, LLC, Fidelity, TCG Crossover Management, LLC, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.48% |
| Fidelity | 8.93% |
| TCG Crossover Management, LLC | 6.16% |
| Aberdeen Group plc | 5.84% |
| First Light Asset Management, LLC | 4.1% |
| abrdn Healthcare Investors | 3.94% |
| Baker Bros. Advisors, LP | 3.11% |
| 5AM Venture Management, LLC | 3.1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.76% |
| Vanguard Group | 4.36% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt